Esperion Therapeutics Inc.
3891 Ranchero Drive
Suite 150
Ann Arbor
Michigan
48108
United States
201 articles about Esperion Therapeutics Inc.
-
Esperion Announces Late-Breaking Presentation of Final Results of Bempedoic Acid Pivotal Phase 3 Study 2 at the American College of Cardiology 2019 Scientific Sessions
3/18/2019
Over 52-Weeks, Bempedoic Acid was Observed to be Safe, Well-Tolerated, and Adverse Event Profile was Similar to that of Placebo
-
Esperion Announces Publication of Bempedoic Acid Study 1 Results in The New England Journal of Medicine
3/13/2019
Over 52-Weeks, Bempedoic Acid was Observed to be Safe, Well-Tolerated, and Did Not Lead to Higher Overall Adverse Events Compared With Placebo
-
Esperion Announces Presentation of Bempedoic Acid Pivotal Phase 3 Study 2 Results in a Late-Breaking Clinical Trial Session at the American College of Cardiology 2019 Scientific Sessions
3/4/2019
Esperion announced that the results from Study 2 of bempedoic acid will be presented in a late-breaking clinical trial session at the American College of Cardiology Scientific Sessions & Expo in New Orleans on Monday, March 18th 2019.
-
Esperion to Participate in Upcoming March 2019 Investor Conferences
3/4/2019
Esperion, the Lipid Management Company focused on developing and commercializing complementary, cost-effective, convenient, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol, today announced that the company will participate in analyst-led fireside chats with investors at the following conferences
-
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Fourth Quarter and Full Year 2018 Financial Results
2/28/2019
Esperion provided bempedoic acid franchise development program updates and financial results for the fourth quarter and year ended December 31, 2018.
-
Esperion Announces Submissions of Two NDAs and Official Completion of Two MAA Validations for Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet
2/28/2019
Esperion announced that the company has successfully completed important and key global marketing applications including the submission of two New Drug Applications for bempedoic acid and the bempedoic acid / ezetimibe combination tablet to the U.S. Food and Drug Administration.
-
With the holidays over and the JP Morgan Healthcare Conference next week, companies were clearly revving their engines, ready to race into the new year. Here’s a roundup of some of the top deals that were announced today.
-
Esperion Announces Agreement with Daiichi Sankyo Europe (DSE) to Commercialize Bempedoic Acid in Europe
1/4/2019
Esperion Therapeutics (NASDAQ: ESPR) today announced that they have entered into a licensing agreement with Daiichi Sankyo Europe (DSE) providing DSE with exclusive rights to commercialize bempedoic acid and the bempedoic acid / ezetimibe combination pill in the European Economic Area and Switzerland.
-
Esperion Announces Late-Breaking Oral Presentation of Final Study 3 Results (1002-046) of Bempedoic Acid at the American Heart Association Scientific Sessions 2018
11/10/2018
Esperion today announced that the final Phase 3 results from Study 3 (1002-046, also known as CLEAR Serenity) were presented at the American Heart Association (AHA) Scientific Sessions in Chicago.
-
Esperion to Participate in Upcoming November 2018 Investor Conferences
11/8/2018
Esperion today announced that the company will participate in analyst-led fireside chats with investors at the following conferences:
-
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter 2018 Financial Results
11/1/2018
Esperion today provided bempedoic acid franchise development program updates and financial results for the third quarter ended September 30, 2018.
-
Shares of Ann Arbor, Mich.-based Esperion Therapeutics are up more than 7 percent in premarket trading after the company announced on Sunday that planned to seek regulatory approval for its cholesterol-lowering therapy that hit the mark in a Phase III trial.
-
Ann Arbor, Mich.-based Esperion Therapeutics is starting off the week with several positives. The company first reported final results from a long-term safety study of bempedoic acid 180 mg versus placebo in high-risk patients with atherosclerotic cardiovascular disease (ASCVD) whose disease is i...
-
Retrophin Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer
7/30/2018
Retrophin, Inc. (NASDAQ: RTRX) today announced the appointment of Noah L. Rosenberg, M.D., as chief medical officer, where he will oversee the clinical development of Retrophin’s product pipeline.
-
Free Technical Research Reports on Biotech Stocks -- Epizyme, Esperion Therapeutics, Exelixis, and Grifols
7/27/2018
On Thursday, July 26, 2018, the NASDAQ Composite closed the trading session at 7,852.18, down 1.01%; the Dow Jones Industrial Average edged 0.44% higher, to finish at 25,527.07; and the S&P 500 closed at 2,837.44, slightly dropping 0.30%.
-
Esperion Announces Third Pivotal Phase 3 Study of Bempedoic Acid Meets Primary Endpoint
5/23/2018
Esperion, the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C), today announced positive top-line results from the third of five pivotal Phase 3 studies (Study 3 or 1002-046) expected to be reported this year.
-
Sanofi and Regeneron have cut deals to dramatically reduce the price of their new cholesterol drug Praluent.
-
Esperion announced that its bempedoic acid for lowering LDL-C cholesterol had positive results in a Phase III clinical trial.
-
5 Tasty Takeover Targets for 2018
1/15/2018
Many investors and analysts expect that the changes to the corporate tax code will lead to increased merger and acquisition activity in 2018. -
Esperion Announces the Appointment of Jeffrey Berkowitz to Board of Directors
12/15/2017
Mr. Berkowitz is the former executive vice president of Optum.